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Endothelial dysfunction is a critical factor during the initiation of cardiovascular complications in diabetes. Berberine can amelio-
rateendothelialdysfunctioninducedbydiabetes.However,theunderlyingmechanismsremainunclear.Theaimofthisstudywasto
investigatetheprotectiveeffectandmechanismofberberineonpalmitate-inducedendothelialdysfunctioninhumanumbilicalvein
endothelialcells(HUVECs).ThecellviabilityofHUVECswasdeterminedbyMTTassays.Nitricoxide(NO)levelandproduction
of reactive oxygen species (ROS) were determined in supernatants or in the cultured HUVECs. The mRNA level of endothelial
nitric oxide synthase (eNOS) was measured by RT-PCR, and the protein levels of eNOS, p-eNOS, Akt, p-Akt, AMPK, p-AMPK,
andNADPHoxidase (NOX4)wereanalyzed. The resultsdemonstrated that berberinesignificantlyelevated NOlevels andreduced
the production of ROS. The expressions of eNOS were significantly increased, while NOX4 protein expression was decreased in
berberine-treated HUVECs. Moreover, berberine upregulated the protein expression of AMPK and p-AMPK in palmitate-treated
HUVECs, but had no effect on the levels of Akt. Therefore, berberine ameliorates palmitate-induced endothelial dysfunction by
upregulating eNOS expression and downregulating expression of NOX4. This regulatory effect of berberine may be related to the
activation of AMPK.
1. Introduction
Cardiovascular complications are main causes of high mor-
tality and morbidity induced by obesity, diabetes, and met-
abolic syndrome. Endothelial dysfunction has been known
as a critical factor and main pathological change during the
development of vascular complication [1]. Lipid metabolic
disorder plays a vital role in the pathogenesis of endothelial
dysfunction in obesity, insulin resistance, and diabetes. An
abnormality in patients with all of these disorders is an
increase in the plasma concentration of free fatty acids (FFA)
[2]. Elevated FFA may cause a series of pathophysiological
changes in the endothelium, including endothelial nitric
oxide synthase (eNOS) uncoupling, intracellular accumu-
lation of reactive oxygen species (ROS), and cell apopto-
sis, which in turn contribute to accelerating the endothe-
lium dysfunction associated with excessive acceleration of
atherosclerosis. Studies showed that high concentration of
FFA impair the eNOS activity and reduce the production and
bioactivityofNOinendothelialcells.FFAoverloadattenuates
Ca
2+ signaling and eNOS activity, reduces NO production,
andindirectlyleadstoendothelialdysfunctioninendothelial
cells [1]. Ye-rong found that elevated FFA could inhibit
eNOS phosphorylation and its gene expression, decrease
endothelium-derived NO production, and thus lead to an
impairment of vasodilation in metabolic syndrome [3].2 Mediators of Inflammation
Moreover, FFA-induced endothelium dysfunction is related
to the activity of NADPH oxidase, the most important
enzyme for the production of O2
−
, within the vascular wall.
As O2
− inactivates NO to form peroxynitrite (ONOO
−), it
triggers a series of harmful events such as decreasing NO
bioavailability, reducing the production of NO, and causing
impaired vasodilatation [4]. Inoguchi et al. reported high
g l u c o s el e v e la n dF F A( p a l m i t a t e )s t i m u l a t eR O Sp r o d u c t i o n
through PKC-dependent activation of NAD(P)H oxidase in
cultured aortic smooth muscle cells and endothelial cells,
which in part accounted for the excessive acceleration of
atherosclerosis in patients with insulin resistance and dia-
betes [5]. Elevated FFAs not only inhibit the eNOS/NO
signalpathwayanddecreaseNOproduction,butalsoactivate
NADPH oxidase, increase production of O2
−,a n dr e d u c e
NO bioactivity during the development of atherosclerosis
a n dt h r o m b o s i si nv a s c u l a rc o m p l i c a t i o n sa s s o c i a t e dw i t h
obesity and diabetes. As matter of relevance, it also has been
establishedthatimpairedeNOSactivityuponpalmitatestim-
ulationmaybelinkedtotolllikereceptor4(TLR4)signaling,
which is a critical mediator of palmitate-induced IKK𝗽
and NF-𝜅B activation, and subsequent decreases in insulin
signaling and NO production in endothelial cells [6, 7].
Decreasing lipotoxicity may be a key component to
prevent and treat cardiovascular complications of metabolic
syndrome. Rhizoma Coptidis (root of Coptis chinensis from
Ranunculaceae) has been used in traditional Chinese med-
icine for more than 1000 years. Berberine, an isoquinoline
alkaloid, a major active component of Rhizoma Coptidis
[8], has been well reported with pleiotropic pharmacological
activities, including antibacterial, antibiotic, anti-inflamma-
tory, and antioxidant properties, as well as ameliorating
effects on hyperlipidemia and hyperglycemia. Recently, both
animalandclinical studies havedemonstratedthatberberine
improves insulin resistance, decreases blood glucose levels,
regulates lipid metabolism, and inhibits the progression of
obesity and diabetes [8–11]. Whether berberine can improve
endothelium dysfunction and prevent the cardiovascular
complications associated with these disorders causes a great
interest to researchers. Tang et al. reported that berberine
had antioxidant effects and could increase the protective
effectondiabeticcomplications[12].Haoetal.demonstrated
that berberine ameliorates diabetic microendothelial injury
induced by the combination of high glucose and advance
glycation end products in vitro [13]. Our previous study
indicatedthatberberinenotonlymodulatesglucoseandlipid
metabolism but also ameliorates endothelial dysfunction in
diabetic rats induced by high fat diet combined with strep-
tozotocin injection. However, the underlying mechanism
through which berberine improves the endothelial dysfunc-
tion to prevent the vascular complications in obesity and
diabetes mellitus is still unclear. There has been no report
about the effect of berberine on the lipotoxicity in the
endothelium dysfunction yet. Therefore, the present study
was to elucidate the protective effects and underlying mech-
anism of berberine on endothelial dysfunction induced by
high doses of palmitate, which could provide evidence for
berberine’s clinical applications in the future.
2. Materials and Methods
2.1. Materials. Human umbilical vein endothelial cells
(HUVECs) were obtained from American Type Culture
Collection (ATCC, USA). RPIM-1640 medium and other
cul t u r er ea g e n t sw e r eo b ta i n edfr o mG i bc oLi f eT ec h n o l o gi e s
(Gibco, Grand Island, NY, USA). Berberine was kindly
provided by Northeast General Pharmaceutical Factory
(Changchun, China). Palmitate, N
G-nitro-L-arginine (L-
NA), 2,7-dichlorodihydrofluorescein diacetate (DCHF-DA),
andthiazolylblue(MTT)werepurchasedfromSigma(Sigma
Aldrich, St. Louis, MO, USA). Bovine serum albumin (BSA,
fatty acid free) was purchased from Wako pure chemical
industries (Japan). Kit for measuring NO was provided
from Nanjing Jiancheng Chemical Factory (Nanjing, China).
eNOS primers were synthesized by Lianxing Biotechnology
(Dalian,China).PolyclonalantibodiesofeNOS,Akt,AMPK,
a n dN O X 4w e r ep u r c h a s e df r o mS a n t aC r u zB i o t e c h n o l o g y
(Santa Cruz Biotechnology, CA). Chemical agents for
western blot and RT-PCR were obtained from Sigma
Aldrich. All other chemical reagents were purchased from
commercial source.
2.2. Cell Culture. HUVECs were cultured in RPIM-1640
medium supplemented with 10% fetal bovine serum (FBS)
and passaged according to the recommended procedures of
ATCC. Cells in passages 4–8 were used for experiments;
cells were exposed to exogenous free fatty acid (0.5mmol/L
palmitate) for 12h or 24h treated with or without different
concentrations of berberine (1.25, 2.5 and 5𝜇mol/L).
2.3. Preparation of Free Fatty Acid-Albumin Complexes.
Lipid-containingmediawerepreparedbyconjugationofFFA
to BSA using a modified method described [14]. Briefly,
p a l m i t a t ew a sd i s s o l v e di n0 . 1 MN a O Hs o l u t i o ni n7 0
∘C
water bath for fully dissolving. Then the 0.1M sodium
palmitate was mixed with 5% fatty acid-free BSA at 1:9 ratio
and left for one hour in 37
∘Ci n c u b a t o r .1 0 m Mp a l m i t a t e
stock solution was stored at −4
∘C. Before experiment, the
stocksolutionwasdilutedinthecompleteculturemediumto
t h er e q u i r e dc o n c e n t r a t i o n ,a d j u s t e dt oap Hv a l u eo f7 . 5 ,a n d
filtersterilized.Thecontrolsolutioncontainingfattyacid-free
BSA was prepared in the same way.
2.4. Cell Viability Assays. The viability of the HUVECs was
determined by MTT assays. Briefly, cells were plated for 24h
in a 96-well plate at a density of 1 × 10
4 cells per well in
200𝜇Lm e d i u m .W h e nc e l l sg r e wt o6 0 %t o7 0 %c o n fl u e n c e ,
the medium was changed to one containing 2% FBS and
0.5mmol/L palmitate (sovled in 4.5% free fatty acid free
BSA) or treated with different concentrations of berberine
(1.25, 2.5, and 5𝜇mol/L). Each treatment was repeated in
6 wells. The cells were incubated for 20h at 37
∘Ci na
humidified chamber. MTT reagent (20𝜇L, 5mg/mL in PBS)
w a sa d d e dt oe a c hw e l la n di n c u b a t e df o r4h .Th em i c r o p l a t e
containing the cells was centrifuged at 1,800rpm for 5min
at 4
∘C. The MTT solution was removed from the wells by
aspiration. The formazan crystals were dissolved in 150𝜇LMediators of Inflammation 3
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Figure 1: The effects of berberine on viability of HUVECs exposed
to palmitate. HUVECs were cultured in RPMI-1640 containing
0.5mmol/L palmitate and treated with 1.25, 2.5, and 5𝜇mol/L
berberine for 24h. Cell viability was measured by MTT assay
and normalized to cells incubated in control medium. Data were
expressed as mean ± S.E.M.
∗𝑃 < 0.05 versus control.
DMSO. Absorbance was recorded at 570nm wavelength
u s i n gaM i c r o p l a t eR e a d e r .C e l lv i a b i l i t yw a sc a l c u l a t e da s
follows: cell viability (100%) = absorbance of experiment
group/absorbance of control group × 100%.
2.5. Measurement of NO Level. H U V E C sw e r eg r o w ni n9 6 -
well dishes. When cells grew to 60% confluence, the medium
waschangedtoonecontaining2%FBS.Thecellsweretreated
with 0.5mmol/L palmitate and various concentrations of
berberine dissolved in ethanol for 24h. The same volume of
ethanol was included in each control group. NO release in
cultured supernatants was determined by the Griess method
[15].
2.6. Measurement of ROS Level. HUVECs were plated in 24-
well dishes at a density of 6 × 10
4 cells per well in 500𝜇Lo f
complete medium. When cells grew to 60% confluence, the
medium was changed to one containing 2% FBS. The cells
were treated with 0.5mmol/L palmitate and various concen-
trationsofberberinefor12h.2,7-Dichlorodihydrofluorescein
diacetate (DCFH-DA, 10 𝜇M, Sigma) staining was employed
for ROS analysis as described previously [16].
2.7. RNA Extraction and Semiquantitative RT-PCR. Total
RNA was extracted from HUVECs using Trizol reagent
(Invitrogen). RNA samples were quantified by spectropho-
tometry, and the integrity was assured by 1.5% agarose gel
electrophoresis and ethidium bromide staining. The first-
strand cDNAs were synthesized from 5g total RNA, using
SuperScript reverse transcriptase and oligo deoxythymidine
primers. The reverse transcription products were amplified
by PCR, using Taq DNA polymerase and specific primers
for Human eNOS (forward: 5
򸀠-GTGATGGCGAAGCGA-
GTGAAG-3
򸀠;r e v e r s e :5
򸀠-CCGAGCCCGAACACACAG-
AAC-3
򸀠, 422bp) and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, forward: 5
򸀠-CCATGGAGAAGGCTGGG-
3
򸀠;r e v e r s e :5
򸀠-CAAAGTTGTCATGGATGACC-3
򸀠, 194bp).
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Figure 2: The effects of berberine on NO production in HUVECs
exposed to palmitate. HUVECs were cultured in RPMI-1640 con-
taining 0.5mmol/L palmitate and treated with 1.25, 2.5, and
5𝜇mol/L berberine for 24h. The control group was not stimulated
with 0.5mmol/L palmitate. L-NA: N
G-nitro-L-arginine. Data are
expressed as mean ± S.E.M.
∗𝑃 < 0.05 versus control group,
#𝑃<
0.05 versus palmitate treated group.
The cycling conditions were 94
∘Cm e l t i n g ,6 0
∘Ca n n e a l i n g ,
and 72
∘C extensions for 30sec (30 cycles for eNOS and 28
cycles for GAPDH). The amplification conditions were opti-
mizedinp r e limin a rys t udiest or es ul tina m p lifica tio nwi thin
the linear range. PCR products were visualized on 1.5%
agarosegelsbyethidiumbromidestainingandgelswerepho-
tographed under UV light. Relative gene expression was
quantified by being densitometrically analyzed using image
software. GAPDH transcript abundance was considered as
an internal control to which eNOS transcript abundance was
normalized.
2.8. Western Blot Analysis. Protein samples were prepared
from cultured HUVECs with ice-cold cell protein lysates.
Protein concentrations were measured using Bradford assay
(Bio-rad protein assay kit). The protein samples (60𝜇g)
were denatured by boiling for 5min, separated by 10% SDS-
polyacrylamidegel,andthenelectroblottedat4
∘Ca n dtr a n s -
ferred onto a polyvinylidene difluoride (PVDF) membrane
(Bio-Rad). The membranes were blocked in 5% (w/v) nonfat
m i l kf o r2ha tr o o mt e m p e r a t u r ea n dt h e ni n c u b a t e dw i t h
rabbit polyclonal antibodies (eNOS, 1:800; Akt, 1:1000;
AMPK, 1:1000; NOX4, 1:1000, Santa Cruz Biotechnology)
with gentle agitation overnight at 4
∘C. The membranes were
washed 3 times for 10min each with 15 mL of TBST (10mM
Tris-HCl, 150mM NaCl, and 0.1% (v/v) Tween-20) and
then incubated with the second antibody (1:1000 goat Anti-
rabbit IgG Horseradish Peroxidase Conjugate, Santa Cruz
Biotechnology) at room temperature for 2h. The protein
was then visualized with enhanced chemiluminescence solu-
tion and X-ray film. To correct for differences in protein
loading, the membranes were washed and reprobed with
1:2000dilutiongoatpolyclonalantibodytoactin(SantaCruz
Biotechnology). An imaging densitometer was used to scan
theproteinbandsandquantifythemusingtheimageanalysis
software.4 Mediators of Inflammation
(a) (b) (c)
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Figure 3: The effects of berberine on ROS in HUVECs exposed to palmitate. HUVECs were cultured in RPMI-1640 containing 0.5mmol/L
palmitate and treated with 1.25, 2.5, and 5𝜇mol/L berberine for 12h. HUVECs were labeled with DCFH-DA for 20min and ROS generation
was analyzed by fluorescence detection with Confocal microscopy at 200x. (a) HUVECs were cultured in RPMI 1640 without palmitate; (b)
HUVECs were stimulated by 0.5mmol/L palmitate; ((c), (d) and (e)) HUVECs were stimulated by 0.5mmol/L palmitate and treated with
1 . 2 5 ,2 . 5 ,a n d5𝜇mol/L berberine, respectively.
2.9. Statistical Analysis. All data were expressed as mean ±
S.E.M. The “𝑛”d e n o t e dt h es a m p l es i z ei ne a c hg r o u p .Th e
statistical analyses were performed using one-way analysis
of variance (ANOVA) followed by the Tukey post-hoc test.
SPSS software (version 13.0 for Windows) was used for the
statistical analysis. 𝑃 < 0.05 was considered to be statistically
significant.
3. Results
3.1. Effect of Berberine on HUVECs Viability. HUVECs via-
bility in the palmitate treated group fell to 70.03 ± 3.06%
comparedwiththatinthegroupwithoutpalmitatetreatment.
Afterberberine(1.25∼5.0𝜇mol/L)treatmentinHUVECs,the
cell viability was increased from 71.27 ± 3.05%t o77.27 ±
2.70%( Figure 1). Although this difference did not reach
statistical significance, but the increased trend could be
observed. In preliminary experiments, we found that higher
concentrations of berberine (>5.0𝜇mol/L) induced toxici-
ties to HUVECs (data not shown). Accordingly, different
concentrations of berberine (1.25∼5.0𝜇mol/L) were selected
in the following studies.
3.2. Effect of Berberine on NO Levels in Cultured Medium
of HUVECs. HUVECs cultured with 0.5mmol/L palmitate
displayed a remarkable decrease in NO release compared
withthatofHUVECswithoutpalmitatetreatment(Figure 2).
Berberine treatment significantly increased NO release as
compared with untreated palmitate HUVECs. Berberine
5.0𝜇m o l / Lh a dt h es t r o n g e s te ff e c to nN Or e l e a s e .e N O S
inhibitor L-NA partially inhibited the effect of berberine
on NO release. These results suggest that palmitate could
reduce NO synthesis and release in cultured HUVECs, while
berberine could significantly rescue the NO production
which might be related to eNOS, the key enzyme of NO
synthesis in endothelial cells.
3.3. Effect of Berberine on ROS in HUVECs. As shown in
Figure 3,thegreenfluorescentintensityinHUVECscultured
with palmitate was significantly enhanced compared with
that in the control group, which suggested that intracellular
ROS levels in palmitate stimulated HUVECs were markedly
increased. Berberine treatment decreased intracellular fluo-
rescence intensity in a dose-dependent manner comparedMediators of Inflammation 5
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Figure 4: The effects of berberine on eNOS mRNA expression in
HUVECs exposed to palmitate. HUVECs were cultured in RPMI-
1640containing0.5mmol/Lpalmitateandtreatedwith1.25,2.5,and
5𝜇mol/L berberine for 24h. Total RNA was extracted and RT-PCR
was performed. All values were normalized to 100% for the value
of the control and were expressed as the percentage of the control.
Data are mean ± S.E.M. The control group was not stimulated with
0.5mmol/L palmitate. All presented results are representative of at
least 3 independent experiments.
∗𝑃 < 0.05 versus control group.
#𝑃 < 0.05 versus palmitate treated group.
with palmitate group. These results indicate that palmitate
could stimulate significantly the increase in ROS production
and release from HUVECs, which might be related to cell
injury caused by oxidative stress. It was believed that berber-
inetreatmentcouldreducetheproductionofROSinducedby
high palmitate cultured HUVECs and play a protective effect
on endothelial cells.
3.4.EffectofBerberineoneNOSmRNAExpression. Palmitate
treatment significantly reduced eNOS mRNA expression in
HUVECs versus control group (Figure 4), while intrigu-
ingly, berberine treatment can rescue the eNOS mRNA in
palmitate-HUVECs in a dose-dependent manner (𝑃 < 0.05).
3.5. Effect of Berberine on Signaling of eNOS, Akt, and AMPK.
To investigate whether berberine treatment could activate
eNOS and its upstream kinase, Akt and AMPK in cultured
HUVECs, eNOS, Akt, and AMPK protein expression were
analyzed by western immunoblotting (Figure 5). The protein
expression of eNOS and phosphorylation of eNOS were
significantly reduced in HUVECs stimulated by palmitate
compared to that of controls cells (Figure 5(a)). Berberine
significantly increased eNOS and phosphorylation of eNOS
proteinexpression.Comparedwiththegroupwithoutpalmi-
tate,proteinexpressionoftotalAkthadnosignificantchange
in HUVECs cultured with palmitate, while phosphorylation
of Akt expression markedly decreased. Berberine treatment
did not change the expression of Akt and p-Akt in HUVECs
stimulated by palmitate (Figure 5(c)). However, the protein
expression of AMPK, another upstream kinase of eNOS in
endothelial cells, was significantly lowered in HUVECs cul-
tured with palmitate compared with control group (with-
out palmitate). Berberine increased not only the protein
expression of total AMPK but also the phosphorylation of
AMPK (Figure 5(b)). These results indicate that palmitate
could downregulate eNOS expression in cultured HUVECs.
Berberine treatment could reverse this change which might
contribute to the activation of AMPK, promoting eNOS
phosphorylation. While Akt/eNOS signaling pathway might
not be involved.
3.6. Effect of Berberine on Protein Expression of NOX4. In
contrast to eNOS expression, NOX4 protein expression, a
main subunit of NADPH oxidase in vascular endothelium,
was markedly enhanced in HUVECs stimulated by palmi-
tate (Figure 6). Berberine treatment decreased the protein
expression of NOX4 in HUVECs cultured with palmitate
comparedwithcontrolgroup(withoutpalmitate).Itsuggests
that berberine could reduce ROS levels by downregulating
NOX4 expression.
4. Discussion
Increased oxidative stress and reduced NO bioavailability are
important contributing factors and are closely related with
inflammatory signaling pathways such as toll like receptor
4 signaling in the pathogenesis of endothelial dysfunction,
hypertension,andcardiovascularandrenaldiseases[17].Our
previous studies showed that berberine restored endothelial
vasodilationfunctionunder diabetic conditionby enhancing
NO bioavailability. In the present study, the direct effect of
berberine on NO and ROS production was further observed
in palmitate-induced endothelial injury of HUVECs. The
results showed that the survival rate of HUVECs cultured
with 0.5mM palmitate for 24h was significantly decreased.
Moreover, berberine treatment significantly increased NO
content in the supernatant of HUVECs cultured with palmi-
tate. These results indicated that the protective effect of
berberine on endothelial dysfunction induced by FFA might
be associated with the elevation of NO levels.
eNOS is a key enzyme that produces NO in vascular
endothelial cells. Studies on endothelial cells have demon-
strated that FFA elevation in the culture medium can signifi-
cantly decrease the activity of eNOS [18]. Palmitate and oleic
a c i dc o u l di n h i b i tt h ep h o s p h o ry l a t i o no fe N O Ss e r 1 1 7 7s i t e s ,
in turn reduce the NO production, which may contribute to
endothelialdysfunctionandtheoccurrenceofatherosclerosis
[18]. Healthy SD rats were administered fat emulsion and
heparininintravenousinfusion;theelevatedFFAlevelinhib-
itedeNOSactivityandexpressionandreducedendothelium-
derived NO production in turn [19]. It has been reported
that endothelium-derived NO production was mediated by
Akt/eNOS signaling pathway [20]. In accordance with these
findings, our results showed that palmitic acid significantly
decreased the expression of eNOS in cultured HUVECs.
Berberine treatment upregulated the expression of eNOS
mRNA and total protein and promoted the phosphorylation6 Mediators of Inflammation
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Figure 5: The effects of berberine on protein expression of eNOS, p-eNOS, Akt, p-Akt, AMPK, and p-AMPK in HUVECs exposed to palmi-
tate.HUVECswereculturedinRPMI-1640containing0.5mmol/Lpalmitateandtreatedwith1.25,2.5,and5𝜇mol/Lberberinefor24h.Total
protein was prepared and separated by SDS-PAGE. Expression and relative quantification of eNOS, Akt, and AMPK and phosphorylation
of eNOS, Akt, and AMPK protein levels were expressed relative to the amount of actin. Control group was not stimulated with 0.5mmol/L
palmitate. Data are mean ± S.E.M. All presented results are representative of at least 3 independent experiments.
∗𝑃 < 0.05 versus control
group,
#𝑃 < 0.05 versus palmitate treated group.
ofeNOSatser1177sites,therebyincreasingtheNOsynthesis.
Moreover,L-NA,oneofeNOSinhibitors,partiallyattenuated
NO production stimulated by berberine. Furthermore, it can
be seen in the present study that palmitic acid remarkably
reduced the phosphorylation of Akt in HUVECs. However,
berberine did not affect the expression of Akt and its
phosphorylation in HUVECs cultured with palmitic acid. It
migh tindica tetha tberberinemigh texerti tsr egula to ryeff ect
on eNOS activity by other ways.
Adenosine monophosphate-activated protein kinase
(AMPK), as an intracellular energy receptor, has attracted
more attention and become a new target for the treatmentMediators of Inflammation 7
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Figure6:TheeffectsofberberineonproteinexpressionofNOX4in
HUVECs exposed to palmitate. HUVECs were cultured in RPMI-
1640 containing 0.5mmol/L palmitate and treated with 1.25, 2.5,
and 5𝜇mol/L berberine for 24h. Total protein was prepared and
separated by SDS-PAGE. Expression and relative quantification of
NOX4 protein levels were expressed relative to the amount of actin.
Control group was not stimulated with 0.5mmol/L palmitate. Data
are expressed as mean ± S.E.M. All presented results are representa-
tive of at least 3 independent experiments.
∗𝑃 < 0.01 versus control
group,
#𝑃 < 0.05 versus palmitate treated group, and
##𝑃 < 0.01
versus palmitate treated group.
of diabetes and its cardiovascular complications due to its
regulatory effect on endothelial cell function and energy
homeostasis in recent years. AMPK plays an important role
in regulating function of NO synthesis signaling pathways
in endothelial cells. AMPK, an upstream kinase of eNOS,
promotes the phosphorylation of eNOS Ser1177 site. AMPK
can promote the formation of eNOS and HSP90 complex as
well, thereby activating eNOS [17, 21]. Our results showed
that berberine could significantly upregulate the expression
levels of AMPK and p-AMPK protein of HUVECs cultured
with palmitic acid, but had no effect on the expression of
Akt and p-Akt protein. Accordingly, we speculated that the
regulatory effect of berberine on eNOS activity and NO
production might be related to the activation of AMPK
partially.
Furthermore, endothelial dysfunction is also correlated
with the production of ROS in vascular endothelial cells
besides the decrease of NO production. It has been broadly
accepted that elevated ROS levels are primarily derived from
the action of NADPH oxidase (NOX). Activation of NOX
couldimprovetheROSformationandcontributetoendothe-
lial dysfunction [22]. NOX4 is a subtype of NADPH oxidase
expressed mainly in vascular endothelial cells, and it is the
mainsourceofO2
− productionintheendothelialcells.Inthe
presentstudy,ROSproductionandNOX4proteinexpression
were measured in cultured HUVECs. Our results showed
thatpalmiticacidsignificantlyincreasedROSproductionand
the expression of NOX4 protein in cultured HUVECs. While
berberine reduced ROS production and decreased protein
expression of NOX4. These results are consistent with our
previous findings from the diabetes animal models.
Several lines of studies indicated that AMPK is an
important inhibitor of NADPH oxidase in cardiovascular
cells. The activation of AMPK reduced ROS production
by inhibiting the activity of NADPH oxidase and finally
prevented the endothelial cell apoptosis induced by palmitic
acid [23]. AMPK activators such as metformin may exert
their cardiovascular protective function through NOX inhi-
bition [24]. AMPK activation suppresses NOX activity may
either block NOX phosphorylation and translocation to
cell membrane or inactivate transcription factors including
NF-𝜅Ba n dS T A T[ 25]. Therefore, berberine might prevent
endothelial dysfunction from FFA-induced ROS generation
by activation of AMPK. Taken together, berberine inhibits
eNOS activation and NOX4-derived ROS accumulation in
the HUVECs treated with FFA through AMPK activation,
which may contribute to the protective effects of berberine
on endothelial function. However, in our experiments, the
specificinhibitorofAMPKwasnotused.Itwasstillunknown
whether the effect of berberine on the regulation of eNOS
and NOX4 can be blocked by AMPK inhibitor, which
should be explored to clarify the molecular mechanisms in
the future studies. Furthermore, it has been reported that
berberine could inhibit the TLR4-NF𝜅B pathway in LPS-
induced intestinal injury in mice, a pathway involved in
the impairment of eNOS expression and NO production.
This might be another mechanism involved in the protective
effect of berberine on endothelial dysfunction and still needs
further investigation [26].
In summary, the present study investigated the protective
effect of berberine on the vascular endothelial function in
cell injury model induced by palmitic acid incubation, and
revealedtheunderlyingmechanismthroughwhichberberine
can significantly ameliorate the endothelial dysfunction.
BerberinecouldupregulateeNOSexpression,enhanceeNOS
activity, and promote NO production. Meanwhile, berberine
could downregulate NADPH oxidase expression and inhibit
its activity to reduce ROS production and then inhibit NO
inactivation as well. Thereby, berberine treatment could
enhance the biological activity of NO to protect the vascular
endothelial cell function. In our study, we also found that
t h er e g u l a t o r ye ff e c to fb e r b e r i n eo ne N O Sa n dN A D P H
oxidase activity may be related to the activation of AMPK.
These results provide an important theoretical evidence for
the application of berberine in the prevention and treatment
of obesity, diabetes, and their cardiovascular complications.
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